Biotech · Private company
Genetix Biotherapeutics Inc.
Track this companyFree. Adds Genetix Biotherapeutics Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials167 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- bb1111Phase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Lenti-DPhase 3 · Cerebral Adrenoleukodystrophy (CALD)ClinicalTrials.gov · fetched Nov 12, 2026
- Lenti-D Drug Product (eli-cel)Phase 3 · Cerebral Adrenoleukodystrophy (CALD)ClinicalTrials.gov · fetched Nov 12, 2026
- LentiGlobin BB305 Drug ProductPhase 3 · Beta-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
- LentiGlobin BB305 Drug ProductPhase 2 · β-thalassemia MajorClinicalTrials.gov · fetched Nov 12, 2026
- lovo-celPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Allo-HSCTX-Linked Adrenoleukodystrophy (X-ALD)ClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionBeta-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
- No InterventionCerebral Adrenoleukodystrophy (CALD)ClinicalTrials.gov · fetched Nov 12, 2026
- No interventional drug product utilized in this follow-up studyCerebral Adrenoleukodystrophy (CALD)ClinicalTrials.gov · fetched Nov 12, 2026
- Safety and efficacy assessmentsSickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Safety and efficacy assessmentsTransfusion-dependent Beta-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials16
- A Study of Participants With Cerebral Adrenoleukodystrophy (CALD) Treated With Elivaldogene AutotemcelRECRUITING · started Mar 27, 2024ClinicalTrials.gov NCT06224413 · fetched Nov 12, 2026
- A Study of Participants with Β-Thalassemia Treated with Betibeglogene AutotemcelRECRUITING · started Jan 23, 2024ClinicalTrials.gov NCT06271512 · fetched Nov 12, 2026
- A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 12, 2022ClinicalTrials.gov NCT05353647 · fetched Nov 12, 2026
- Study of MGTA-145 and Plerixafor in Patients With Sickle Cell DiseasePHASE2 · TERMINATED · started Jun 24, 2022ClinicalTrials.gov NCT05445128 · fetched Nov 12, 2026
- Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene TherapyENROLLING_BY_INVITATION · started Oct 21, 2020ClinicalTrials.gov NCT04628585 · fetched Nov 12, 2026
- A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell DiseasePHASE3 · ACTIVE_NOT_RECRUITING · started Feb 14, 2020ClinicalTrials.gov NCT04293185 · fetched Nov 12, 2026
- A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)PHASE3 · COMPLETED · started Jan 24, 2019ClinicalTrials.gov NCT03852498 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-ThalassemiaPHASE3 · COMPLETED · started Jun 8, 2017ClinicalTrials.gov NCT03207009 · fetched Nov 12, 2026
- A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 GenotypePHASE3 · COMPLETED · started Aug 8, 2016ClinicalTrials.gov NCT02906202 · fetched Nov 12, 2026
- Long-term Follow-up of Participants With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug ProductACTIVE_NOT_RECRUITING · started Jan 22, 2016ClinicalTrials.gov NCT02698579 · fetched Nov 12, 2026
- Study of bb2121 in Multiple MyelomaPHASE1 · COMPLETED · started Dec 22, 2015ClinicalTrials.gov NCT02658929 · fetched Nov 12, 2026
- Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)TERMINATED · started Apr 1, 2015ClinicalTrials.gov NCT02204904 · fetched Nov 12, 2026
- A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell DiseasePHASE1_PHASE2 · COMPLETED · started Feb 2, 2015ClinicalTrials.gov NCT02140554 · fetched Nov 12, 2026
- Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene TherapyACTIVE_NOT_RECRUITING · started Jan 1, 2014ClinicalTrials.gov NCT02633943 · fetched Nov 12, 2026
- A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)PHASE2_PHASE3 · COMPLETED · started Aug 21, 2013ClinicalTrials.gov NCT01896102 · fetched Nov 12, 2026
- A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major ParticipantsPHASE1_PHASE2 · COMPLETED · started Aug 1, 2013ClinicalTrials.gov NCT01745120 · fetched Nov 12, 2026